What is BridgeBio Pharma's restricted cash?

BridgeBio Pharma (BBIO) reported restricted cash of $550K in Q1 2026.

How has BridgeBio Pharma's restricted cash changed year-over-year?

BridgeBio Pharma's restricted cash increased by 336.5% year-over-year, from $126K to $550K.

What is the long-term trend for BridgeBio Pharma's restricted cash?

Over 4 years (2020 to 2024), BridgeBio Pharma's restricted cash has grown at a -2.4% compound annual growth rate (CAGR), from $139K to $126K.

BridgeBio Pharma BBIO Restricted Cash

Restricted Cash at other companies

Revolution Medicines, Inc.RVMD

$4.86M+31.4%

IncyteINCY

$1.84M+10.3%

ALN

Alnylam PharmaceuticalsALNY

——

Roivant SciencesROIV

——

Neurocrine BiosciencesNBIX

——

ViatrisVTRS

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's restricted cash?: BridgeBio Pharma (BBIO) reported restricted cash of $550K in Q1 2026.
How has BridgeBio Pharma's restricted cash changed year-over-year?: BridgeBio Pharma's restricted cash increased by 336.5% year-over-year, from $126K to $550K.
What is the long-term trend for BridgeBio Pharma's restricted cash?: Over 4 years (2020 to 2024), BridgeBio Pharma's restricted cash has grown at a -2.4% compound annual growth rate (CAGR), from $139K to $126K.